Display options
Share it on

Pharmacy (Basel). 2017 Jul 25;5(3). doi: 10.3390/pharmacy5030041.

Knowledge, Attitude and Advice-Giving Behaviour of Community Pharmacists Regarding Topical Corticosteroids.

Pharmacy (Basel, Switzerland)

Wing Man Lau, Parastou Donyai

Affiliations

  1. Reading School of Pharmacy, University of Reading, PO Box 226, Whiteknights, Reading RG6 6AP, UK. [email protected].
  2. Reading School of Pharmacy, University of Reading, PO Box 226, Whiteknights, Reading RG6 6AP, UK. [email protected].

PMID: 28970453 PMCID: PMC5622353 DOI: 10.3390/pharmacy5030041

Abstract

This study examines the relationship between community pharmacists' knowledge, attitudes to information provision and self-reported counselling behaviours in relation to topical corticosteroids and adjunct therapy in atopic eczema. A mixed-methods approach was used whereby data from interviews with community pharmacists were used to design a structured questionnaire that a larger sample of community pharmacists completed anonymously. The questionnaire was completed and returned by 105 pharmacists (36% response rate). Pharmacists showed gaps in their knowledge on the use of topical corticosteroids in atopic eczema but had good understanding on the use of emollients. There was a significant correlation between pharmacists' attitudes to information provision and their self-reported counselling behaviour for most themes except in relation to corticosteroid safety where less advice was given. Improving attitudes to information provision should correlate with increased counselling behaviour. However, for the theme of corticosteroid safety, further studies are needed to examine why in practice pharmacists are not providing patient counselling on this topic even though most agreed this is a topic patients should know about.

Keywords: attitudes; community pharmacist; patient counselling; topical corticosteroids

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Lancet. 1989 Jul 15;2(8655):155 - PubMed
  2. Br J Dermatol. 2008 May;158(5):917-20 - PubMed
  3. J Eur Acad Dermatol Venereol. 2003 Nov;17(6):652-8 - PubMed
  4. Br J Dermatol. 2000 May;142(5):931-6 - PubMed
  5. J Dermatolog Treat. 2006;17(3):136-42 - PubMed
  6. Australas J Dermatol. 1996 May;37 Suppl 1:S10-3 - PubMed
  7. Australas J Dermatol. 2010 Aug;51(3):168-74 - PubMed
  8. J Am Acad Dermatol. 2005 Jul;53(1):41-51 - PubMed
  9. Ann Pharmacother. 2010 Jan;44(1):70-9 - PubMed
  10. Br J Dermatol. 2007 Feb;156(2):203-21 - PubMed
  11. Int J Pharm Pract. 2014 Apr;22(2):119-24 - PubMed
  12. Australas J Dermatol. 2015 Sep 22;:null - PubMed
  13. Br J Dermatol. 2003 Sep;149(3):582-9 - PubMed
  14. Clin Exp Dermatol. 2003 Sep;28(5):549-53 - PubMed
  15. J Dermatolog Treat. 2007;18(4):209-18 - PubMed
  16. J Invest Dermatol. 2014 Jun;134(6):1527-1534 - PubMed
  17. Acta Derm Venereol. 2016 Feb;96(2):177-80 - PubMed
  18. Int J Clin Pharmacol Ther Toxicol. 1991 Feb;29(2):48-50 - PubMed
  19. Australas J Dermatol. 2016 Aug;57(3):199-204 - PubMed
  20. Am J Hypertens. 2010 Sep;23(9):949-55 - PubMed
  21. Int J Pharm Pract. 2015 Dec;23 (6):390-8 - PubMed
  22. Int J Pharm Pract. 2012 Oct;20(5):344-6 - PubMed

Publication Types